1007219-73-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1-methylindazole-6-carboxylate is used as a synthetic intermediate for the development of N-benzoylindazole derivatives and analogues. These derivatives have potential applications as inhibitors of human neutrophil elastase, an enzyme involved in various inflammatory processes and diseases.
Methyl 1-methylindazole-6-carboxylate is also used as a synthetic intermediate in the preparation of indazole-pyridine based protein kinase/Akt inhibitors. These inhibitors play a crucial role in regulating cellular processes such as cell survival, growth, and apoptosis, making them important targets for the development of therapeutic agents against various diseases, including cancer.

Upstream product

• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 74-88-4 methyl iodide 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 67-56-1 methanol 
• 590417-94-0 6-bromo-1-methyl-1H-indazole 
• 201230-82-2 carbon monoxide 

Downstream Products

• 1031417-77-2 1-methyl-1H-indazole-6-carboxylic acid 

Relevant academic research and scientific papers

Synthetic method 1 - methyl - 111H-indazole -6 - formic acid (by machine translation)

The invention provides a synthetic method, 1 - methyl - 111H-indazole -6 - formic acid. The synthesis method comprises 2 - fluorine -4 - bromobenzaldehyde and methylhydrazine as a raw material, and after the cyclization reaction is carried out 6 - bromo -1 - methyl indazole, then formate esterification reaction and hydrolysis reaction, and the 1 - methyl - 111H (indazole -6 - formic acid; isomers, and the like 1 are avoided, and the problem that impurities are difficult to remove in follow-up separation is avoided. Not only is the product purity, the yield of ring-forming 85% reaction can also reach the unitunits ?, the yield is higher, the product is suitable for small-scale preparation in laboratories, production, reaction conditions are easy to operate, control, production cost, and large-scale industrial production are facilitated. (by machine translation)

HISTONE DEMETHYLASE INHIBITORS

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

ORNITHINE DERIVATIVE

Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.